Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 2
2006 2
2007 2
2008 1
2009 4
2010 2
2011 5
2012 8
2013 6
2014 9
2015 13
2016 7
2017 7
2018 12
2019 9
2020 16
2021 15
2022 9
2023 10
2024 9
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS.
DeZern AE, Thepot S, De Botton S, Patriarca A, Deeren D, Torregrose Diaz JM, Marconi G, Bernal Del Castillo T, Bergua Burgues JM, Xicoy B, Jonasova A, Zeidan AM, Dimicoli-Salazar S, Simand C, Valcárcel D, Díez-Campelo M, Chai-Ho W, Saini L, Garnier A, Geissler K, Ofran Y, Nagy Z, Krishnamurthy P, Lübbert M, Basak GW, Carraway HE, Sallman DA, Borate U, Santini V, Campbell V, Fenaux P, Braun T, Lanza F, Zaucha JM, Roth DA, Paul S, Roy P, Kelly M, Volkert A, Chisolm J, Abdul Malak T, Klimek V, Cluzeau T. DeZern AE, et al. Blood Adv. 2025 May 7:bloodadvances.2025016229. doi: 10.1182/bloodadvances.2025016229. Online ahead of print. Blood Adv. 2025. PMID: 40334070
Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT.
Swoboda R, Labopin M, Giebel S, Maertens J, Parovichnikova E, Versluis J, Pavlu J, Kopinska A, Capria S, Raida L, Rambaldi A, Caillot D, Folber F, Nachbaur D, Ozturk M, Aljurf M, Rubio MT, Gorin NC, Lanza F, Nagler A, Mohty M, Ciceri F. Swoboda R, et al. BMC Cancer. 2025 Apr 28;25(1):787. doi: 10.1186/s12885-025-14126-8. BMC Cancer. 2025. PMID: 40289118 Free PMC article.
Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party.
Abou Dalle I, Labopin M, Khvedelidze I, Baron F, Brissot E, Bug G, Esteve J, Giebel S, Gorin NC, Lanza F, Nagler A, Peric Z, Piemontese S, Ruggeri A, Sanz J, Savani B, Schmid C, Shouval R, Spyridonidis A, Versluis J, Ciceri F, Bazarbachi A, Mohty M. Abou Dalle I, et al. Bone Marrow Transplant. 2025 Jun;60(6):921-923. doi: 10.1038/s41409-025-02576-4. Epub 2025 Apr 15. Bone Marrow Transplant. 2025. PMID: 40229537 No abstract available.
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.
Nanni J, Azzali I, Papayannidis C, Mulè A, Audisio E, Martelli MP, Scappini B, Chiusolo P, Cambò B, Candoni A, Lunghi M, Albano F, Olivieri A, Fracchiolla N, Bernardi M, Romani C, Rigolin GM, Giannini MB, Bocchia M, Todisco E, Cilloni D, Bochicchio MT, Ottaviani E, Mattei A, Zamagni F, Valli I, Volpi R, Marconi G, Petracci E; FLAM Collaborative Group; Martinelli G. Nanni J, et al. Cancer. 2025 Apr 1;131(7):e35824. doi: 10.1002/cncr.35824. Cancer. 2025. PMID: 40159434 Free PMC article.
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Papayannidis C, Petracci E, Zappasodi P, Fracchiolla N, Ciceri F, Sartor C, Roncoroni E, Di Raimondo F, Mattei D, Giannini MB, Lanza F, Gottardi M, Del Principe MI, Borlenghi E, Fumagalli M, Vallisa D, Sica S, Di Renzo N, Fabbiano F, Todisco E, de Fabritiis P, Luppi M, Passamonti F, Corradini P, Petruzziello F, Pane F, Ferrara F, Mambelli G, Volpi R, Frabetti F, Zingaretti C, Marconi G, Martinelli G. Papayannidis C, et al. Cancer. 2025 Apr 1;131(7):e35820. doi: 10.1002/cncr.35820. Cancer. 2025. PMID: 40120068 Free PMC article.
Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia.
de Lima M, Kebriaei P, Lanza F, Cho C, Popradi G, Kaur M, Zhang MJ, Zhang F, Shah R, Vandendries E, Asomaning K, Dorman S, Stelljes M, Marks DI, Saber W. de Lima M, et al. Am J Hematol. 2025 May;100(5):909-912. doi: 10.1002/ajh.27637. Epub 2025 Feb 24. Am J Hematol. 2025. PMID: 39989181 Free PMC article. No abstract available.
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.
Marconi G, Petracci E, Lanzarone G, Vetro C, Martelli MP, Papayannidis C, Audisio E, Minetto P, Riva C, Guolo F, Martini G, Zappasodi P, Vincenzo F, Gigli F, Griguolo D, Rondoni M, Ciotti G, Borlenghi E, Ciccone N, Palumbo FE, Nanni J, Mattei D, Bernardi M, Cignetti A, Zingaretti C, Vertogen B, Cerchione C, Lanza F, Cilloni D, Brunetti L, Palmieri R, Curti A, Giannini MB, Todisco E; AVALON research group; Fracchiolla N, Martinelli G. Marconi G, et al. Am J Hematol. 2025 Apr;100(4):708-711. doi: 10.1002/ajh.27591. Epub 2025 Jan 20. Am J Hematol. 2025. PMID: 39831709 Free PMC article.
142 results